Expression profiling of circulating tumor cells
13th OctoberResearchers from University of Essen in collaboration with Qiagen and TATAA stratify breast cancer patients based on expression profiling of circulating tumor cells
Circulating tumor cells (CTC) are thought to be an ideal surrogate marker to monitor disease progression in metastatic breast cancer (MBC).We investigated the prediction of treatment response in CTC of MBC patients on the basis of the expression of 46 genes.
CTCs are proposed to be an attractive source of liquid biopsy markers for monitoring disease progression. CTCs are highly heterogeneous and can change in number and phenotype under anticancer treatment. Stem cell-like tumor cells, undergoing epithelial-mesenchymal-transition (EMT) and not displaying the classical epithelial phenotype, are discussed as an active source of metastatic spread and have been identified within the population of CTCs.
> TATAA GrandPerformance Assays – Cancer Panel
> TATAA PreAmp GrandMaster® Mix
> ValidPrime® Control for Genomic Background
